Qiang YU - 澳门大学 - 健康科学学院

个人简介

Education Ph.D. Cancer Pharmacology, Queen’s University, Kingston, Ontario, Canada (1998) M.Sc. Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (1991) M.B. Qingdao University Medical College, China (1985) Academic and Professional Experience 2016-present Adjunct Professor, Faculty of Health Sciences, University of Macau 2011-present Senior Group Leader, Cancer Biology and Pharmacology, Genome Institute of Singapore 2011-present Adjunct Professor, Department of Physiology, National University of Singapore 2011-present Adjunct Professor, Cancer and Stem Cell Biology, DUKE-NUS 2006-2011 Adjunct Associate Professor, Department of Physiology, National University of Singapore 2006-2011 Group Leader, Cancer Biology and Pharmacology, Genome Institute of Singapore 2002-2006 Senior Scientist and Principle Investigator, Cancer Biology and Pharmacology, Genome Institute of Singapore 2000-2002 Visiting Fellow Advanced Technology Center National Cancer Institute Gaithersburg, MD. USA. 1998-2001 International Fogarty Fellow Laboratory of Molecular Pharmacology, National Cancer Institute Bethesda, MD, USA 1991-1993 Research Associate, Institute of Medical Sciences, Chinese Academy of Medical Sciences

研究领域

Patents 2013 201208522-1 A Novel Reagent For Gene-Drug Therapeutics 2013 201208522-1 A Novel Reagent For Gene-Drug Therapeutics 2013 201304198-3 Rasal2 is a biomarker associated with triple negative breast cancer early relapse 2012 201107036-4 STS1 (UBASH3B) is a novel druggable target for invasive breast and prostate cancers 2010 GIS/Z05818 A biomarker for rapamycin resposne 2009 PCT/SG2009/000356 DZNep analogs as anti-cancer agents 2006 PCT/SG2006/000350 Methods for Cancer Therapy and Stem Cell Modulation 2005 PCT/SG2007/000058 Mothods for senstizing DNA Damage Response: A Potential Target for Cancer Therapy 2005 PCT/SG2006/000053 Methods for Assessing Suitability of Cancer Patients for Treatment with Histone Deacetylase Inhibitors 2004 PCT/SG2005/000223 Modulation of GSK-3 beta and Method of Treating Proliferative Disorders

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Representative Publications Wee ZN, Yatim SM, Kohlbauer VK, Feng M, Goh JY, Yi B, Lee PL, Zhang S, Wang PP, Lim E, Tam WL, Cai Y, Ditzel HJ, Hoon DS, Tan EY, Qiang Yu “IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.” Nat Commun 2015 ; 6 : 8746 Feng M, Bao Y, Li Z, Li J, Gong M, Lam S, Wang J, Marzese DM, Donovan N, Tan EY, Hoon DS, Qiang Yu. “RASAL2 activates RAC1 to promote triple-negative breast cancer progression.” J Clin Invest , 2014 Dec;124(12):5291-304 Tan J, Li Z, Lee PL, Guan P, Aau M, Lee ST, Feng M, Lim CZ, Lee EY, Wee ZN, Lim YC, Karuturi RK, Yu Q. “PDK1 Signaling Towards PLK1-Myc Activation Confers Oncogenic Transformation and Tumor Initiating Cell Activation and Resistance to mTOR-targeted Therapy.” Cancer Discov 2013 Oct;3(10):1156-71 Shuet Theng Lee1, Min Feng, Yong Wei, Zhimei Li, Yuanyuan Qiao1, Peiyong Guan, Meiyee Aau, Xia Jiang, Chew Hooi Wong, Kelly Huynh, Jinhua Wang, Juntao Li, K. Murthy Karuturi, Ern Yu Tan, Dave SB Hoon, Yibin Kang, Qiang Yu. Protein Tyrosine Phosphatase UBASH3B is Overexpressed in Triple-Negative Breast Cancer and Promotes Invasion and Metastasis. Proc Natl Acad Sci U S A, 2013 Jul 2;110(27):11121-6 Shuet Theng Lee, Zhimei Li, Zhenlong Wu, Meiyee Aau, Peiyong Guan, R.K. Murthy Karuturi, Yih Cherng Liou and Qiang Yu .”Context-Specific Regulation of NF-kB Target Gene Expression by EZH2 in Breast Cancers”. Molecular Cell , 43, 798–810, 2011 Jing Tan, Puay Leng Lee, Zhimei Li, Xia Jiang, Yaw Chyn Lim, Shing Chuan Hooi and Qiang Yu. B55β-associated PP2A complex controls PDK1-directed Myc signaling and modulates rapamycin sensitivity in colorectal cancer. Cancer Cell, 18:459-471, 2010 Xiaojing Yang, Min Feng, Xia Jiang, Zhenlong Wu, Meiyee AAu, Zhimei Li, and Qiang Yu. miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. Genes & Development . 2009 23: 2388-2393 Xia Jiang, Jing Tan, Jingsong Li, Saul Kivimäe, Xiaojing Yang1 Li Zhuang, Puay Leng Lee, Mark TW. Chan, Lawrence Stanton, Edison T. Liu, Benjamin N.R.Cheyette and Qiang Yu. DACT3 is an epigenetic regulator of Wnt/β-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell. 13:529, 2008. PMID: 18538736 Jing Tan, Xiaojing Yang, Li Zhuang, Xia Jiang, Wei Chen, Puay Leng Lee, RK Murthy Karuturi, Patrick Boon Ooi Tan, Edison T. Liu and Qiang Yu. Pharmacologic disruption of Polycomb repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes & Development. 2007 21:1050. PMID: 17437993 Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, Shahab A, Yong HC, Fu Y, Weng Z, Liu J, Zhao XD, 4 Chew JL, Lee YL, Kuznetsov VA, Sung WK, Miller LD, Lim B, Liu ET, Yu Q, Ng HH, Ruan Y (2006). A global map of p53 transcription-factor binding sites in the human genome. Cell. 124(1):207-19. PMID: 16413492